CN116077554B - Preparation method of Guanxinning composition - Google Patents
Preparation method of Guanxinning composition Download PDFInfo
- Publication number
- CN116077554B CN116077554B CN202211509444.9A CN202211509444A CN116077554B CN 116077554 B CN116077554 B CN 116077554B CN 202211509444 A CN202211509444 A CN 202211509444A CN 116077554 B CN116077554 B CN 116077554B
- Authority
- CN
- China
- Prior art keywords
- guanxinning
- percolate
- preparation
- solution
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 239000010093 guan-xin-ning Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000243 solution Substances 0.000 claims abstract description 35
- 239000000706 filtrate Substances 0.000 claims abstract description 22
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims abstract description 9
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 8
- 238000005325 percolation Methods 0.000 claims abstract description 8
- 229920001864 tannin Polymers 0.000 claims description 25
- 235000018553 tannin Nutrition 0.000 claims description 25
- 239000001648 tannin Substances 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 claims description 2
- 229960000989 perhexiline Drugs 0.000 claims description 2
- 235000017276 Salvia Nutrition 0.000 claims 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 abstract description 47
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 17
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 17
- 235000001785 ferulic acid Nutrition 0.000 abstract description 17
- 229940114124 ferulic acid Drugs 0.000 abstract description 17
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 17
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 17
- 229930183118 Tanshinone Natural products 0.000 abstract description 14
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 abstract description 14
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 abstract description 13
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 abstract description 13
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 abstract description 13
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 abstract description 13
- 229930183842 salvianolic acid Natural products 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 7
- 235000005412 red sage Nutrition 0.000 abstract description 7
- 241000112528 Ligusticum striatum Species 0.000 abstract description 5
- 241000212322 Levisticum officinale Species 0.000 abstract description 3
- 239000001645 levisticum officinale Substances 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 34
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 18
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 18
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 16
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 15
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 15
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 12
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 12
- 229930183325 senkyunolide Natural products 0.000 description 12
- RSKPJCDZAFMWHH-UHFFFAOYSA-N 3-but-1-enyl-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(C=CCC)OC(=O)C2=C1 RSKPJCDZAFMWHH-UHFFFAOYSA-N 0.000 description 11
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 9
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 9
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229960003371 protocatechualdehyde Drugs 0.000 description 8
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 7
- DQNGMIQSXNGHOA-UMEXKXKESA-N (3e,6s,7s)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one Chemical compound C1([C@@H]([C@@H](O)CC2)O)=C2C(=C/CCC)\OC1=O DQNGMIQSXNGHOA-UMEXKXKESA-N 0.000 description 6
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- DQNGMIQSXNGHOA-UHFFFAOYSA-N senkyunolide-H Natural products C1CC(O)C(O)C2=C1C(=CCCC)OC2=O DQNGMIQSXNGHOA-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- -1 ketone compound Chemical class 0.000 description 4
- 229930189533 tanshinol Natural products 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- DQNGMIQSXNGHOA-RCBCECLLSA-N (3z,6s,7r)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one Chemical compound C1([C@H]([C@@H](O)CC2)O)=C2C(=C/CCC)/OC1=O DQNGMIQSXNGHOA-RCBCECLLSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- YUFZXVOYNSJPSJ-UHFFFAOYSA-N 1-methyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-6,10,11-trione Chemical compound O=C1C(=O)C2=C3CCCC(=O)C3=CC=C2C2=C1C(C)=CO2 YUFZXVOYNSJPSJ-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UPCWCCRFMPIOAP-UHFFFAOYSA-N Hydroxytanshinone Chemical compound C1=CC(C(CCC2O)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 UPCWCCRFMPIOAP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- UJZQBMQZMKFSRV-RGKBJLTCSA-N (2s,3s)-4-[(e)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 UJZQBMQZMKFSRV-RGKBJLTCSA-N 0.000 description 1
- PTDUBPDLRWKSBQ-UHFFFAOYSA-N 3-beta-hydroxytanshinone IIA Natural products C1=CC(C(C(O)CC2)(C)C)=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 PTDUBPDLRWKSBQ-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- UJZQBMQZMKFSRV-PHQFMFTGSA-N Lithospermic acid Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@@H](C(=O)O)[C@H](c3cc(O)c(O)cc3)Oc2c(O)cc1 UJZQBMQZMKFSRV-PHQFMFTGSA-N 0.000 description 1
- NFOCYHUCMXEHDG-UHFFFAOYSA-N Monomethyl lithospermate Natural products COC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(O)=O)CC1=CC=C(O)C(O)=C1 NFOCYHUCMXEHDG-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930194268 Salvianic acid Natural products 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FAMPSKZZVDUYOS-UHFFFAOYSA-N alpha-Caryophyllene Natural products CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- MONRRGJOOZMWNB-UHFFFAOYSA-N ethyl lithospermate Natural products CCOC(=O)C1C(C=2C=C(O)C(O)=CC=2)OC(C(=CC=2)O)=C1C=2C=CC(=O)OC(C(=O)OC)CC1=CC=C(O)C(O)=C1 MONRRGJOOZMWNB-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a preparation method of a Guanxinning composition, which belongs to the technical field of traditional Chinese medicine preparations, and the preparation method is that red sage root and szechuan lovage rhizome are extracted by an ethanol aqueous solution with the concentration of 80-85wt% through a percolation method, and percolate and dregs are obtained; treating the percolate to obtain percolate; the dregs are treated, and the obtained decoction filtrate is mixed with the percolate to obtain a mixed solution; the mixed solution is adopted to prepare the Guanxinning composition. The invention adopts ethanol water solution with specific concentration and adopts a percolation method to extract, so that the effective components of salvianolic acid (especially salvianolic acid B), tanshinone and ferulic acid contained in the salvia miltiorrhiza and the ligusticum wallichii can be effectively reserved, and the effective components are not degraded, thereby improving the content of the effective components in the Guanxin composition.
Description
Technical Field
The invention relates to a traditional Chinese medicine preparation, in particular to a preparation method of a Guanxinning composition.
Background
The coronary heart disease relieving medicine is a compound traditional Chinese medicine preparation which is composed of red sage root and szechuan lovage rhizome and has the effects of activating blood circulation to dissipate blood stasis, promoting blood circulation to nourish heart, regulating qi and relieving pain. Pharmacological studies show that the coronary heart disease treating injection has the functions of dilating coronary artery, promoting coronary collateral circulation, accelerating the repair of ischemic myocardium, protecting ischemic and anoxic myocardium, and the like, and is clinically mainly used for treating cardiovascular and cerebrovascular diseases such as coronary heart disease, angina pectoris, cerebral embolism, and the like. The chemical components in red sage root are classified into water-soluble and fat-soluble. The water soluble components mainly comprise phenolic compounds, polysaccharides and pachyma, including salvianic acid, caffeic acid, rosmarinic acid, salvianolic acid, lithospermic acid and ethyl lithospermate, and protocatechuic aldehyde, protocatechuic acid, etc. The liposoluble component is mainly conjugated quinone and ketone compound, including tanshinone, cryptotanshinone, hydroxy tanshinone, methyl tanshinol, methine tanshinone, tanshinol, 3 alpha-hydroxy tanshinone IIA, nortanshinone, tanshinol, and tanshinol. The rhizoma Ligustici Chuanxiong mainly contains volatile oil compounds such as ligustilide, 3-butylphthalide, butylphthalide and caryophyllene; alkaloids such as ligustrazine and choline; organic acids such as ferulic acid, sirtuin, rhein, palmitic acid, chrysophanol, and caffeic acid.
The existing method for preparing the Guanxinning mainly comprises the steps of removing macromolecular substances such as protein, pectin and the like through water decoction and alcohol precipitation, removing tannins through acid-base treatment or removing tannins through macroporous resin, and then decoloring, adding auxiliary materials and the like to prepare the preparation.
However, because the chemical components of salvianolic acid (especially salvianolic acid B), tanshinone, ferulic acid and the like contained in the red sage root and the ligusticum wallichii are easy to degrade when heated in the water decoction process, the content of the salvianolic acid in the water decoction is affected, and the drug effect is further affected; meanwhile, volatile oil compounds in the ligusticum wallichii volatilize along with the temperature rise in the water decoction process, so that the curative effect of the guanxinning is further affected; and because part of the effective components are fat-soluble compounds, the fat-soluble compounds are extracted by a water decoction mode, the extraction rate of the fat-soluble compounds is low, and the curative effect of the Guanxin is also influenced.
Disclosure of Invention
In order to solve the problems, the invention provides a preparation method of a Guanxinning composition.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a method of preparing a perhexiline composition, the method comprising the steps of:
extracting Saviae Miltiorrhizae radix and rhizoma Ligustici Chuanxiong with 80-85wt% ethanol water solution by percolation method to obtain percolate and residue;
treating the percolate to obtain percolate;
the dregs are treated, and the obtained decoction filtrate is mixed with the percolate to obtain a mixed solution;
the mixed solution is adopted to prepare the Guanxinning composition.
Further, the treatment mode of the percolate is that after the percolate is concentrated, gelatin solution with the weight percent of 4 percent is dripped to remove tannins, and the percolate is obtained by refrigerating and filtering.
Further, the density of the percolate after concentration is 1.15-1.20.
Further, in the treatment process of the percolate, the refrigerating time is more than 24 hours.
Further, the process of preparing the guan Xin ning composition by the mixed solution is that the mixed solution is ultrafiltered, the pH value is regulated, and the guan Xin ning composition is obtained by preparation treatment of the guan Xin ning solution.
Further, the weight ratio of the red sage root to the ligusticum wallichii is 1:1;
after ultrafiltration, the pH value is regulated to 5.5-6.0.
Further, the preparation treatment is to take a Guanxinning solution to prepare a liquid preparation or a solid preparation;
the liquid preparation comprises but is not limited to injection, transfusion or oral liquid;
the solid formulations include, but are not limited to, granules, tablets, capsules or pills.
Further, the extraction time of the percolation method is 4-6 hours.
Further, the treatment process of the dregs is to take dregs and decoct with water for 2 times, each time for 1-1.5 hours, combine decoctions, filter, concentrate, add ethanol until the alcohol content is 85%, cool and filter, concentrate filtrate again until the relative density is 1.15-1.20, add gelatin solution of 4wt% to remove tannins, cool and filter, concentrate filtrate at 70 ℃ to obtain fluid extract with the relative density of 1.10-1.15, adjust pH value to 2-3 with hydrochloric acid, cool and filter, and obtain the decoction filtrate.
Further, when the dregs are decocted, the water is 4 to 6 times of the weight of the red sage root or the szechuan lovage rhizome;
the decoction is mixed and filtered, and then concentrated until the relative density is 1.16-1.26.
The preparation method of the Guanxinning composition has the beneficial effects that:
the invention adopts ethanol water solution with specific concentration to extract by percolation method, can effectively keep the effective components of salvianolic acid (especially salvianolic acid B), tanshinone and ferulic acid contained in the red sage root and the ligusticum chuanxiong rhizome to be extracted without degradation, thereby improving the content of the effective components in the guanxinning composition;
the invention adopts ethanol water solution with specific concentration to carry out diacolation extraction, can effectively extract liposoluble effective components such as tanshinone, cryptotanshinone, ligustilide, butenyl phthalide and the like, and further improves the curative effect of the Guanxin composition;
the invention can effectively extract volatile oil compounds (such as ligustilide, butenyl phthalide and the like) contained in the ligusticum wallichii by adopting ethanol water solution with specific concentration for diacolation extraction, thereby preventing the volatile oil compounds from volatilizing;
the invention adopts ethanol water solution with specific concentration to carry out diacolation extraction, which can inhibit macromolecular substances such as protein, polysaccharide and the like from being dissolved in diacolation liquid, thereby reducing the amount of impurities required to be treated in the alcohol precipitation process;
according to the invention, 4wt% gelatin solution is dripped into the percolate (or liquid obtained after decoction alcohol precipitation), so that the gelatin solution can fully form precipitation with tannins in the percolate (or liquid obtained after decoction alcohol precipitation) to remove the tannins, the tannins treatment process is simplified, and meanwhile, the decomposition of substances such as salvianolic acid (especially salvianolic acid B), protocatechol, ferulic acid, and deluxe acid caused by pH change in the process of removing the tannins by adding alkali is avoided;
the invention can effectively extract the water-soluble effective components such as senkyunolide and the like remained in the medicine residues after the completion of percolation by re-using water for decoction of the medicine residues;
the invention is regulated to a specific pH value in the preparation process, and can effectively maintain the stability of the substances such as salvianolic acid (especially salvianolic acid B), protocatechol, ferulic acid, and the like in the subsequent preparation process;
the invention has simple process route and convenient operation, and is suitable for industrial production.
Detailed Description
The following description of the technical solution in the embodiments of the present invention is clear and complete. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.
Example 1A method for preparing a Guanxinning composition
The embodiment is a preparation method of a Guanxinning composition, and the specific preparation process comprises the following steps in sequence:
1) Soaking 1000g of radix Salviae Miltiorrhizae and 1000g of rhizoma Chuanxiong in 85wt% ethanol water solution, percolating and extracting for 5 hr to obtain percolate and residues;
2) Concentrating the percolate to a relative density of 1.20, dropwise adding 4wt% gelatin solution under stirring until no precipitate is generated, refrigerating at 2deg.C for 24 hr, and filtering to obtain percolate;
decocting the residues with 5 times of water (the multiple of water is the multiple of the weight of radix Salviae Miltiorrhizae or rhizoma Chuanxiong, i.e. 5 kg) for 2 times, each time for 1h, mixing decoctions, filtering, concentrating the filtrate to relative density of 1.24, adding ethanol to ethanol content of 85%, refrigerating at 2deg.C for 24h (i.e. ethanol precipitation), filtering, concentrating the filtrate again to relative density of 1.20, dripping 4wt% gelatin solution until no precipitate is generated, refrigerating at 2deg.C for 24h, filtering, recovering ethanol from the filtrate until no ethanol smell, diluting with injectable water, refrigerating, filtering, concentrating the filtrate again at 70deg.C to obtain fluid extract with relative density of 1.15, adjusting pH to 2.5 with 10wt% hydrochloric acid, refrigerating, and filtering to obtain decoction filtrate;
3) Mixing the percolate and the decoction filtrate, ultrafiltering the obtained mixture (removing microorganism, heat source, etc.), and adjusting pH to 5.5 to obtain GUANXINNING solution, labeled as M1;
taking a Guanxin solution M1, fixing the volume to 1000mL, filling, sealing and sterilizing to obtain a Guanxin liquid preparation (marked as G1), wherein the Guanxin liquid preparation contains 38.7231mg/mL of salvianolic acid B, 0.9214mg/mL of tanshinone I, 1.3675mg/mL of tanshinone IIA, 1.3627mg/mL of ferulic acid, 0.7243mg/mL of cryptotanshinone, 37.9465mg/mL of ligustilide, 0.4798mg/G of protocatechuic aldehyde, 2.9614mg/mL of rosmarinic acid, 0.3971mg/mL of ligustrazine, 0.9215mg/G of senkyunolide I, 0.2627mg/G of senkyunolide H, 4.678 mg/G of senkyunolide A, 0.4896mg/mL of butenyl phthalide and 2.1mg/mL of tannins.
The content of the active ingredient in the Guanxinning liquid preparation G1 is detected according to the method in the content determination of the ingredient in Guanxinning 14 (Li Qingqing, zhang Jifen, modern salt chemical industry, period 6 of 12 months in 2019); the content of tannin is based on quality study of Guanxinning injection of different manufacturers (Li Xiangming, etc., modern Chinese medicine, volume 36, 2 nd stage of 2016, 03 month)
The guanxinning liquid preparation comprises but is not limited to injection, transfusion or oral liquid.
The GUANXINNING liquid preparation can also be prepared by adding other conventional adjuvants (such as correctant in oral liquid), metering volume to 1000mL, packaging, and sterilizing.
Alternatively, the guan Xin ning solution M1 is lyophilized to obtain guan Xin ning lyophilized powder, which is marked as D1.
The guanxinning freeze-dried powder D1 can also be prepared into other types of solid preparations such as granules, tablets, capsules or pills by adopting the conventional technology in combination with common auxiliary materials according to the types of the required preparations.
For example, in the preparation of granule, conventional adjuvants such as filler, wetting agent, disintegrating agent, and binder can be added; conventional processes such as wet granulation or dry granulation can be used in the preparation process.
In the process of preparing the tablet, conventional auxiliary materials such as filler, wetting agent, disintegrating agent, adhesive and the like can be added; the conventional processes of mixing, stamping and the like are adopted in the preparation process.
When preparing the capsule, conventional auxiliary materials such as filler, lubricant, disintegrating agent and the like can be added; conventional mixing, filling and other conventional processes can be adopted in the preparation process.
When preparing pill, adding conventional adjuvants such as lubricant, binder, and diluent; the preparation process can adopt conventional processes such as traditional molding method, general method and the like.
Examples 2 to 6 Process for the preparation of Guanxinning compositions
Examples 2 to 6 are each a process for the preparation of a composition of Coralline, which steps are substantially the same as in example 1, except for the process parameters, which are specified in Table 1:
table 1 list of process parameters in examples 2 to 6
The process steps and parameters of the other parts of examples 2 to 6 are the same as in example 1.
The Guanxinning solutions M2-M5 can be respectively added or not added with auxiliary materials to prepare liquid preparations, or respectively added or not added with auxiliary materials to prepare solid preparations.
Experimental example 1 comparative test
Comparative examples 1 to 6 are comparative tests of the preparation method of the Coralline composition in example 1, differing only in that:
percolating with 70wt% ethanol water solution to obtain GUANXINNING liquid preparation, labeled DG1, wherein salvianolic acid B24.3274 mg/mL, tanshinone I0.5431 mg/mL, tanshinone IIA0.8651mg/mL, ferulic acid 1.3626mg/mL, cryptotanshinone 0.3574mg/mL, ligustilide 18.1274mg/mL, protocatechuic aldehyde 0.2654mg/g, rosmarinic acid 2.9637mg/mL, ligustrazine 0.3985mg/mL, senkyunolide I0.9208 mg/g, senkyunolide H0.2636 mg/g, senkyunolide A3.1245mg/g, butenyl phthalide 0.3058mg/mL, and tannin 2.2mg/mL; it can be seen that decreasing the ethanol concentration in the aqueous ethanol solution results in decreased extraction of salvianolic acid B, tanshinone I, tanshinone IIA, cryptotanshinone, ligustilide, protocatechuic acid, senkyunolide A, and butenyl phthalide.
Percolating with 95wt% ethanol water solution to obtain GUANXINNING liquid preparation, wherein the preparation is marked as DG1, and the liquid preparation comprises salvianolic acid B35.7216 mg/mL, tanshinone I0.8124 mg/mL, tanshinone IIA 1.2607mg/mL, ferulic acid 1.0103mg/mL, cryptotanshinone 0.6892mg/mL, ligustilide 37.2463mg/mL, protocatechuic aldehyde 0.4214mg/g, rosmarinic acid 2.6385mg/mL, ligustrazine 0.2572mg/mL, senkyunolide I0.8153 mg/g, senkyunolide H0.2452 mg/g, senkyunolide A4.6572mg/g, butenyl phthalide 0.4932mg/mL, and tannin 2.1mg/mL; it can be seen that increasing the ethanol concentration in the ethanol aqueous solution resulted in a decrease in the extraction of salvianolic acid B, tanshinone I, tanshinone IIA, ferulic acid, cryptotanshinone, rosmarinic acid, ligustrazine, senkyunolide I, and senkyunolide H.
Concentrating the percolate and the filtrate after alcohol precipitation in comparative example 3 until the relative density is 1.05, adding 4wt% gelatin solution to obtain a Guanxinning liquid preparation, and marking as DG3, wherein salvianolic acid B38.6894mg/mL, tanshinone I0.9279 mg/mL, tanshinone IIA1.3652mg/mL, ferulic acid 1.3643mg/mL, cryptotanshinone 0.7205mg/mL, ligustilide 37.9458mg/mL, protocatechuic aldehyde 0.4783mg/g, rosmarinic acid 2.9598mg/mL, ligustrazine 0.3954mg/mL, ligustilide I0.9207 mg/g, ligustilide H0.2631 mg/g, ligustilide A4.6775mg/g, butenyl phthalide 0.4879mg/mL, tannin 3.1mg/mL; it can be seen that the content of each active ingredient is not changed obviously, the content of tannins is increased obviously, and the tannins can not be separated out completely probably due to the fact that the concentration of the solution is too low.
The percolate and the filtrate after alcohol precipitation in comparative example 4 are concentrated to 1.35, and then 4wt% gelatin solution is added to obtain a Guanxinning liquid preparation, and the Guanxinning liquid preparation is marked as DG4, wherein 36.2143mg/mL of salvianolic acid B, 0.8763mg/mL of tanshinone I, 1.3215mg/mL of tanshinone IIA, 1.3107mg/mL of ferulic acid, 0.7209mg/mL of cryptotanshinone, 36.1521mg/mL of ligustilide, 0.4123mg/g of protocatechuic aldehyde, 2.6954mg/mL of rosmarinic acid, 0.3438mg/mL of ligustrazine, 0.8709mg/g of senkyunolide, 0.2352mg/g of senkyunolide, 4.2745mg/g of senkyunolide A, 0.4198mg/mL of butenyl phthalide and 2.2mg/mL of tannins; it can be seen that the content of each active ingredient is reduced, and the concentration of the active ingredient is reduced probably because the active ingredient is separated out by the sediment coating in the process of removing tannins by adding gelatin due to the excessive concentration of the solution.
After ultrafiltration in the mixed solution in comparative example 5, the pH value is regulated to 7.0, and the obtained Guanxinning liquid preparation is marked as DG5, wherein 37.0123mg/mL of salvianolic acid B, 0.9201mg/mL of tanshinone I, 3682mg/mL of tanshinone IIA1, 1.3176mg/mL of ferulic acid, 0.7213mg/mL of cryptotanshinone, 36.8794mg/mL of ligustilide, 0.4339mg/g of protocatechuic aldehyde, 2.7253mg/mL of rosmarinic acid, 0.3968mg/mL of ligustrazine, 0.9232mg/g of senkyunolide I, 0.2614mg/g of senkyunolide H, 4.6798mg/g of senkyunolide A, 0.4789mg/mL of butenyl phthalide and 2.1mg/mL of tannin; it can be seen that the change of the pH value in the preparation process can cause the content of the effective components such as salvianolic acid (especially salvianolic acid B), protocatechuic acid, ferulic acid, and the like to be reduced to different degrees, possibly due to the degradation of the effective components to different degrees in the subsequent processes such as ultrafiltration, volume fixation, filling and the like.
The preparation process of comparative example 6 comprises decocting 1000g of Saviae Miltiorrhizae radix and 1000g of rhizoma Ligustici Chuanxiong with 8kg of water for three times, the first time for 2 hours, the second time and the third time for 1.5 hours respectively, mixing decoctions, filtering, concentrating the filtrate to obtain fluid extract with relative density of 1.24, adding ethanol to a content of 85%, refrigerating, filtering, adjusting pH of the filtrate to about 8.3 with 40% sodium hydroxide solution, refrigerating, filtering, recovering ethanol from the filtrate to no alcohol smell, diluting with injectable water to about 1000mL, refrigerating, filtering, concentrating the filtrate to fluid extract with relative density of 1.15 (70deg.C), adjusting pH with hydrochloric acid solution to 2.5, refrigerating, filtering, adjusting pH of the filtrate to 7.0 with 10% sodium hydroxide solution, heating and boiling for 30 min, adding appropriate amount of activated carbon, slightly cooling, filtering, refrigerating, ultrafiltering to adjust pH to 5.5, constant volume to 1000mL, bottling, and sterilizing to obtain GUANXINNING liquid preparation, marked as DG6, wherein salvianolic acid B25.3124 mg/mL, tanshinone I0.0023 mg/mL, tanshinone IIA 0.0037mg/mL, ferulic acid 1.0210mg/mL, cryptotanshinone 0.0015mg/mL, ligustilide 0.0024mg/mL, protocatechuic aldehyde 0.0712mg/g, rosmarinic acid 2.8124mg/mL, ligustrazine 0.3805mg/mL, senkyunolide I0.9205 mg/g, senkyunolide H0.2635mg/g, senkyunolide A0.0049mg/g, butenyl phthalide 0.0008mg/mL, and tannin 4.2mg/mL; it can be seen that the existing method of removing tannins by water alkali treatment can reduce the contents of salvianolic acid B, tanshinone I, tanshinone IIA, ferulic acid, cryptotanshinone, ligustilide, protocatechol, senkyunolide A and butenyl phthalide to different degrees, and the content of tannins is obviously increased, probably because part of fat-soluble active ingredients cannot be well extracted in the water extraction process, volatile ingredients volatilize along with the increase of the water extraction temperature, and easily degradable substances such as salvianolic acid (especially salvianolic acid B), tanshinone, ferulic acid and the like degrade to different degrees along with the increase of the temperature or the subsequent alkali addition to remove the tannins. Meanwhile, the removal effect of the alkali-added tannin is obviously poorer than that of the method.
It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Claims (5)
1. A method of preparing a perhexiline composition, comprising the steps of:
extracting Saviae Miltiorrhizae radix and rhizoma Ligustici Chuanxiong with 80-85wt% ethanol water solution at a weight ratio of 1:1 by percolation method to obtain percolate and residue;
concentrating the percolate to a density of 1.15-1.20, dripping a gelatin solution with the weight percent of 4% to remove tannins, refrigerating, and filtering to obtain a percolate;
decocting the residues in water for 2 times, each time for 1-1.5 hours, mixing decoctions, filtering, concentrating to a relative density of 1.16-1.26, adding ethanol to an alcohol content of 85%, refrigerating, filtering, concentrating the filtrate again to a relative density of 1.15-1.20, adding a gelatin solution with a weight of 4% to remove tannins, refrigerating, filtering, concentrating the filtrate at 70 ℃ to obtain fluid extract with a relative density of 1.10-1.15 at 70 ℃, regulating the pH value to 2-3 with hydrochloric acid, refrigerating, and filtering to obtain a decoction filtrate;
mixing the decoction filtrate and the percolate to obtain a mixed solution;
and (3) taking the mixed solution for ultrafiltration, and then adjusting the pH value to 5.5-6.0, and treating the prepared Guanxin solution by a preparation to obtain the Guanxin composition.
2. The method for preparing a guanxinning composition according to claim 1, wherein the time of cold storage in the percolate treatment process is more than 24 hours.
3. The method for preparing the guanxinning composition according to claim 1, wherein the preparation treatment is to take a guanxinning solution to prepare a liquid preparation or a solid preparation.
4. The method for preparing a guanxinning composition according to claim 1 or 3, wherein the extraction time of the percolation method is 4-6 hours.
5. The method for preparing a guanxinning composition according to claim 1, wherein the water used for decocting the dregs is 4-6 times by weight of the root of red-rooted salvia or the rhizome of chuanxiong.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211509444.9A CN116077554B (en) | 2022-11-29 | 2022-11-29 | Preparation method of Guanxinning composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211509444.9A CN116077554B (en) | 2022-11-29 | 2022-11-29 | Preparation method of Guanxinning composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116077554A CN116077554A (en) | 2023-05-09 |
| CN116077554B true CN116077554B (en) | 2023-12-26 |
Family
ID=86205339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211509444.9A Active CN116077554B (en) | 2022-11-29 | 2022-11-29 | Preparation method of Guanxinning composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077554B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457784A (en) * | 2003-06-05 | 2003-11-26 | 郭东宇 | Method for producing xinnaoning injectin containing chuanxiong rhizome and red sage root extract |
| CN1660191A (en) * | 2004-12-31 | 2005-08-31 | 曹卫中 | Oral preparation of Chinese traditional medicine for treating vascular headache and hemicrania, and preparation method |
| CN1695711A (en) * | 2005-05-23 | 2005-11-16 | 江西本草天工科技有限责任公司 | Diphase capsule of compound dalbergia wood and preparation method |
| CN1732988A (en) * | 2005-08-18 | 2006-02-15 | 中国人民解放军第四军医大学药物研究所 | Capsule with dried human placemta and red sage root and its preparing process |
| CN1803159A (en) * | 2005-01-13 | 2006-07-19 | 天津药物研究院 | Drop pills for treating coronary heart disease and its preparation method |
| CN1810269A (en) * | 2005-01-28 | 2006-08-02 | 天津药物研究院 | Freeze dried perhexiline powder for injection and its prepn process |
| CN1850160A (en) * | 2006-03-08 | 2006-10-25 | 王宗仁 | Qidantongmai Tablet, and its preparing process |
| CN102119965A (en) * | 2010-01-07 | 2011-07-13 | 天津天士力现代中药资源有限公司 | Extract for preventing and treating angina pectoris and preparation method and application thereof |
| CN102441086A (en) * | 2011-11-30 | 2012-05-09 | 中山市中智药业集团有限公司 | Guiqi blood-nourishing oral liquid |
-
2022
- 2022-11-29 CN CN202211509444.9A patent/CN116077554B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1457784A (en) * | 2003-06-05 | 2003-11-26 | 郭东宇 | Method for producing xinnaoning injectin containing chuanxiong rhizome and red sage root extract |
| CN1660191A (en) * | 2004-12-31 | 2005-08-31 | 曹卫中 | Oral preparation of Chinese traditional medicine for treating vascular headache and hemicrania, and preparation method |
| CN1803159A (en) * | 2005-01-13 | 2006-07-19 | 天津药物研究院 | Drop pills for treating coronary heart disease and its preparation method |
| CN1810269A (en) * | 2005-01-28 | 2006-08-02 | 天津药物研究院 | Freeze dried perhexiline powder for injection and its prepn process |
| CN1695711A (en) * | 2005-05-23 | 2005-11-16 | 江西本草天工科技有限责任公司 | Diphase capsule of compound dalbergia wood and preparation method |
| CN1732988A (en) * | 2005-08-18 | 2006-02-15 | 中国人民解放军第四军医大学药物研究所 | Capsule with dried human placemta and red sage root and its preparing process |
| CN1850160A (en) * | 2006-03-08 | 2006-10-25 | 王宗仁 | Qidantongmai Tablet, and its preparing process |
| CN102119965A (en) * | 2010-01-07 | 2011-07-13 | 天津天士力现代中药资源有限公司 | Extract for preventing and treating angina pectoris and preparation method and application thereof |
| CN102441086A (en) * | 2011-11-30 | 2012-05-09 | 中山市中智药业集团有限公司 | Guiqi blood-nourishing oral liquid |
Non-Patent Citations (6)
| Title |
|---|
| 丹参制剂的研究现状及对其开发的几点思考;张军, 刘璐, 赖小平, 刘良;中草药;32(10);954-955 * |
| 丹参制剂的研究进展;尚平;吴琴雪;孙百虎;;河北化工;30(10);12-14 * |
| 冠心宁注射液的二次醇沉及后续工艺改进;高治华;海丽娜;沈达;刘近荣;;中国实验方剂学杂志;19(18);33-35 * |
| 明胶与生药共煮除鞣质方法介绍;姜谋志;张作华;李书桐;;中成药;11(09);47 * |
| 用梯度渗漉法比较丹参有效成分的提取工艺研究;刘杨;尹蓉莉;何芳辉;廖芳;罗燕;赖庆宽;;中成药;30(01);61-63 * |
| 络舒胶囊治疗糖尿病早期血栓状态的临床研究;李郑生;中医药学刊;21(09);1541-1542 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116077554A (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0576456B1 (en) | Pharmaceutical compositions for the treatment of skin disorders | |
| AU2015345884B2 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN103705594A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN116077554B (en) | Preparation method of Guanxinning composition | |
| CN103655791B (en) | A kind of lotus leaf-based preparation for treating phlegm and blood stasis simultaneously and application thereof | |
| CN102772487A (en) | Preparation method of Salvia miltiorrhiza soft capsule | |
| DE19958427A1 (en) | Drug for curing migraine and the preparation method | |
| CN100462077C (en) | Perhexiline injection and its preparing method | |
| WO2024113586A1 (en) | Method for preparing guanxinning composition | |
| CN100488543C (en) | Local externally applied itch stopping garlic liniments | |
| CN112656866A (en) | Peach red four-ingredient particle and preparation method thereof | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN1277548C (en) | Medicine composition for treating cardiovascular and cerebrovascular disease and its prepararing method | |
| CN106890221B (en) | Preparation method of traditional Chinese medicine effective part for treating hyperlipidemia | |
| CN110585295A (en) | Compound itching-relieving granule and preparation method thereof | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| US7179492B2 (en) | Traditional chinese pharmaceutical formulation for treatment of paradentosis, process for preparation and use thereof | |
| CN103933216A (en) | Compound blood pressure lowering capsules for treating metabolic hypertension, preparation method and application thereof | |
| CN116159095B (en) | Preparation method of angelica hexa-yellow Shang Dong dry powder | |
| CN115814041B (en) | A Chinese medicinal composition for treating headache, and its preparation method | |
| CN115120634B (en) | Traditional Chinese medicine compound preparation for preventing and treating alcoholic liver injury and preparation method and application thereof | |
| CN113398232B (en) | Preparation method of pharmaceutical composition for treating gout and gouty arthritis | |
| CN100571728C (en) | A kind of method for preparing WANTONG JINGU PIAN | |
| CN112587584B (en) | Pseudo-ginseng compound composition and application thereof | |
| CN106389592A (en) | Preparation method and application of rhodiola rosea and coffee extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |